More Videos
- Pfizer's Statin Study: What A Coincidence!
- Sam Waksal: "Moving On Up" To The East Side
- Another "Short" Story About Pfizer & Dendreon
- Predictions: 9 For '09 In Pharma
- Johnson & Johnson Is Latest FDA Casualty
- Genentech: Roche Says One Thing, Investors Say Another
- Schering-Plough: The Reviews Are In
- Pharma Updates And What You Need To Know
- The Emails Fly On GM, Ford CEO's Corporate Jets
- Merck Offering To Help Patients—Or Itself?
- Lightning Round: Microsoft, Motorola, NYSE and More
- Lightning Round OT: Hertz, Textron and More
- Mad Mail: Cramer's Plan for the SEC
- The Plaxico Burress Good Judgment Award
- Cramer's Call on Celgene
- Your First Move For Thursday December 4th
- Web Extra: Fast & Furious Trades For Thursday
- Cramer's M&A Plays
- Retailers Move Market?
- Nomura to Cut Up to 1,000 Positions in London
- Capital One to Purchase Chevy Chase
- Australia Economy Injured as Vehicle Sales Crash
- <Headline>Japan Faces Deep Recession, Central Banks Cut Rates</Headline>
- Banks Throw Babcock & Brown a Lifeline
- Japan Capex Data Signals Downward Revision in GDP
- Japan's Nippon Oil, Nippon Mining Plan to Merge
- <Headline>Asian Markets Are Mixed, Focus on Central Banks</Headline>
- Congress Briefed by US Auto Firms on Revamp Plans
Text Size 
 |
CNBC.com |
So far, all of the American big pharmas have filed except for Schering-Plough [SGP
Loading...
()
] . The figures I'm using are from the "Total Compensation" tables, so everything (base salary, bonuses, stock, etc.) and the kitchen sink are thrown in.
Even though it's kind of a hybrid pharma/medicaldevice/consumer products company and not a
 |
CNBC.com |
] Bill Weldon is king of the hill. His total compensation last year was nearly $32 million, up from $28.5 million in 2006. Recently retired Wyeth [WYE
Loading...
()
] chief Bob Essner came in second, despite the fact he took a pay cut during what was a not-so-good year for WYE. He took home $24.1 million, down from $32.8 million the year before. And his successor, Bernard Poussot, pocketed $12.6 million, nearly $2 million less than he got in '06.
Merck's [MRK
Loading...
()
] Dick Clark, who talks about the company's recent stock performance and upcoming catalysts in today's Wall Street Journal nearly doubled his compensation. In 2006, Clark made $10.2 million and last year the company paid him nearly $20 million.
Eli Lilly [LLY
Loading...
()
] also gave its top-two execs a pay cut last year. Sidney Taurel, who is retiring next week, made $13 million, a more than $2 million drop from 2006. And his successor, COO John Lechleiter, also saw his pay shrink by $2 million to $9.3 million.
After being named the permanent head of Bristol-Myers Squibb [BMY
Loading...
()
] , Jim Cornelius got the biggest raise of his peers. He went from nearly $1.5 million in '06 to $11.3 million last year. The company stopped paying for his $25,500 monthly rent plus utilities on his Manhattan apartment last September and revealed it had picked up the tab for $85,000 in private jet fees while Cornelius was interim CEO so he could commute from his home to Bristol HQ in New York.
And then there's Pfizer's [PFE
Loading...
()
] Jeff Kindler. His total compensation saw a slight pullback from $9.7 million in 2006 to $9.5 million in '07. But, the board raised his base salary by $150,000 and gave him a bonus last year equal to 212 percent of his base. In dollars, that equates to a $3.1 million bonus, but the board could have given him as much as $4.3 million extra.
Questions? Comments?
Del.icio.us
Digg It